Shesa's OCTOBER Investment Blog
OCTOBER 2021 - INVESTMENT BLOG
By Shesa Nayak
U.S. Stock Market Commentary
The seismic month of September is out of the door for investors. Last month, we saw all stock indexes DOW, S&P 500 and NASDAQ fell 4.3%, 4.8% and 5.3% respectively, suffering their worst month of this year. Historically, September is the miserable month for investors, but October happens to be a highly volatile month. During October, the volatility is 36% higher than the average of other 11 months of the year. When volatility is higher there are more pullbacks, corrections and bear markets that either start or end in the month. Reminding the investors, the Black Monday of October 1987 was the biggest crash of stock market history when the Dow plummet 22.6% in a single day. Having said that, October has been better than September as stock market has provided much better return (ROI) around 1% since 1980. But that’s the history and it does not necessarily mean history will repeat every year. The economy is confronting with rising inflation, tightening fed, congressional drama on infrastructure bills, fading fiscal stimulus, supply chain issues, global energy crisis, China headwinds and so on.
Elsewhere, the third quarter earnings will kick-off in few days starting with Banks and financial institutions followed by big tech companies. Inflation is ticking up and it does not look like it is transitory anymore but have to stay longer. If the economic situation continues to get better then we could see FED tempering of the asset buying program starting sooner than later. The infrastructure bill and human infrastructure bill constituting $1.2 trillion and $3.5 trillion are in a chaotic condition because of two democrat senators. It seems like a hostage situation, as they are unwilling to negotiate. We will see how it goes but I am hoping that they have to align, negotiate and get it done fast otherwise it would be a disaster for democratic party. With all the doom and gloom, the most exciting thing is we are entering to the best 4 months of the year. Yes, that’s right!! I will write more on this and current stock market situation but before that let’s take a quick look at the stock market indexes.
Indexes | 1/2/21 | Close FRI 10/8/21 | Change in 2021 | % Change in 2021 | All Time High | % From All Time High | From LOW (3/16/20) |
DOW | 30,606.48 | 34,746.25 | 4,139.77 | 13.53 | 35,631.19 | -2.48% | 18213.65 |
S&P 500 | 3,756.07 | 4,391.36 | 635.29 | 16.91 | 4,545.85 | -3.40% | 2191.26 |
NASDAQ | 12,888.28 | 14,579.50 | 1,691.22 | 13.12 | 15,403.44 | -5.35% | 6631.42 |
BTK | 5,739.02 | 5,601.29 | -137.73 | -2.40 | 6376.77 | -12.16% | 3985.72 |
NBI | 4,759.14 | 4,883.29 | 124.15 | 2.61 | 5517.77 | -11.50% | 2947.85 |
S&P 500 Earnings
Earnings: Q3 2021 earnings will start rolling out from 3rd week of October. Financials will be the first sector to start report. The estimated earnings growth is 27.6%, third highest year-over year earnings growth reported by the index since 2010.
Valuation: The forward 12-month P/E ratio for the S&P 500 is 20.5 which is above the 5-year average of 18.3 and above the 10-year average of 16.4.
Source: Factset.com
Economy News
- Minimum Corporate TAX rate of 15% agreed by 136 Countries, implementation starts in 2023
- GDP: Economic grew at 6.7% in the second quarter, according to the Commerce Department. Annual GDP growth stands at 12.2%.
- U.S Coronavirus Cases: 44.3 million vs. 38.8 million during last blog, Death: 713K vs. 637K
- COVID Vaccination: 187 million vs. 173M or 59.7% vs. 52.7% of the U.S population have been fully vaccinated and 61.6% people have taken at least first dose
- Retail Sales: Retail sales were up 0.7% in August
- Unemployment rate: Down to 4.8% vs 5.4% from my previous blog
- US Total GDP/Economy: $20.93 trillion almost unchanged comparing to my last blog
- Interest Rate: 0.25%
- Inflation rate: 5.3% in August vs. 5.4% during my last blog.
- Consumer Confidence: 72.8% in Sept vs. 70.3 in the previous month.
- Business Confidence: 61.1% in Sept vs. 59.9 in August.
- U.S Crude Oil price hits $80 a barrel, the highest since 2014.
Current Economy Scenario
Positives
- COVID Stimulus in 2021: $1.9T (Last year $6.5T)
- Infrastructure Bill: U.S house approved $1.2 trillion but pending for House vote
- American Jobs plan (Human Infrastructure): Climate Change, elderly care, childcare $3.5 trillion planned, still under negotiation
- Q2 GDP growth in 2021: We saw nice growth of 6.7%
- We still expect to see reasonably good earnings growth in Q3, estimated 27.6%
- We are entering into best 4 months of the stock market October through January
- FED has still kept Interest Rates low at 0.25%, and QE is still in place
Negatives
- Inflation picked up significantly, highest since 2008, Inflation rate 5.3% in August. Sept numbers awaited
- Congressional drama on the infrastructure bills, fading fiscal stimulus, supply chain issues, global energy crisis, China headwinds are some of the key negatives
- Still high Unemployment Rate at 4.8%
- A tightening Fed could be seen as an impediment for the stock market
- The earnings and revenue growth will start decelerating from this quarter (Q3) and further deceleration in 2022. Hence, these infrastructure bills are key.
- Corona Virus cases have reduced in last few weeks but will not go away for many more months/years
Stock Market Analysis – Have we hit the Market Top?
As I have stated in my previous blog, September happens to be the worst month for the investors. In other words, it’s THE miserable month for stocks. This September, the S&P 500 saw its seven-month winning streak evaporated, falling 4.8%, the worst month since March 2020. The DOW and the NASDAQ fell 4.3% and 5.3%, respectively, suffering their worst months of this year. But why was it so severe this year? As I said earlier, there were a combination of factors, rising inflation Federal Reserve’s hawkish shift to tighten the bond buying program, slowing economic growth, diminishing consumer confidence, China headwinds and crackdown, congressional drama for the infrastructure bills, fading fiscal stimulus, supply chain issues, global energy crisis are some of the key contributors to these pullbacks.
Navigating to October, Black Monday, the great crash of 1987 occurred on October 19 where the DOW plummeted 22.6% in a single day, is arguably the single worst day of decline in stock market history. The other black days, of course, were part of the process that led to the Great Depression in 1930s. While October is known for notable market crashes, it typically is the start of a better seasonal period for stocks. The S&P 500 averages a 0.9% gain in October since 1980. Historically, the next four months October through January have resulted very good return on investment. Let’s take a look how the market performed in these four months:
October: +0.92%
November: +1.48%
December: +1.11%
January: +0.82%
Source: stockanalysis.com
From the above table, we could conclude that fourth quarter is historically the best for stocks. The stock market have risen in the fourth quarter 79% of the time since 1950, with an average gain of 4%, according to data from Truist Securities. So, would it continue to go up further? History is merely a metrics, we can extrapolate the data and make projections, but future can’t be predicted with certainty.
So, would it continue to go up further this year? Let’s not forget that stocks have gone up significantly in last several years. Since the COVID market collapse in March 2020, DOW has gone up 91%, S&P 500 100% and NASDAQ has gone up 120% from their bottom. So, the next question comes to mind is whether all the good news is behind us and whether market has reached its pick? As far as good news is concerned, I guess the answer is mostly “yes”. We may not see those kind of earnings growth, revenue growth or stimulus program in the foreseeable future. However, if the two infrastructure bill goes through the congress then the momentum can continue
Have we seen the market top?
I do not think so. We have still not seen the irrational exuberance in the stock market. What is this irrational exuberance? This was a term defined by the former Fed chairman Alan Greenspan during the .Com boom of 1999. There is no rampant speculation or highflier stocks going crazy anymore. Well, earlier this year we saw some maniac in the companies like GameStop, AMC, Bed Bath & Beyond, SPAC companies, cannabis stocks, cloud stocks, renewable stocks etc. But today, all those have been beaten to earth. So, those bubbles have already burst, and hype is gone. Occasionally, some stocks may go up like crazy but only a small population of investors are participating in that crazy madness. And this could happen in any market condition. Investors are still willing to buy stocks when there is a pullback.
In April 2021, there was an article in CNBC which said this, “The percentage of investors with $1 million or more in self-managed brokerage accounts sold out of market positions and went to cash in the second quarter were about 16%, according to a survey of wealthy investors conducted by E-Trade/Morgan Stanley. In fact, 42% of the millionaire investors said that they are bearish on the stock market. In other words, the bullishness has declined. Usually, the market top reaches when everybody want to jump to the stock market, start chasing stocks, start talking about stocks wherever they meet and discuss buy this stock, buy that stock and so on. The investors become wildly-confident, bullish, and greedy whereas “bottoms of the stock market” are typically carved out when investors become despairing and hopeless. So, the question is, have we reached to that level of irrational exuberance? certainly not. What it means is, market may have still some space to run. Having said that, it does not mean that market won’t come down. Of course, it’s going to happen, some pullbacks or correction are good things as it brings new investors and new money which helps the overall growth of the stock market in the long run. Nothing goes straight up, if that happens that’s the time to ring the alarm bell.
Critical Infrastructure Bill, what’s happening?
The drama continues for the $1.2 trillion infrastructure bill and $3.5 trillion human infrastructure bill. No doubt these are huge package, but it’s not earth shattering. Let’s think for a moment, these spending are NOT for one year. This is supposed to be spread across 10 years. So, essentially it’s $350B per year. It can be noted that U.S defense budget only for this year is $768 billion. It means, if we do the math U.S spends around $8 trillion in defense for 10 years. Strengthening the country’s defense is absolutely essential but then how much should be spent is another bigger question. A potential government shutdown was averted last Thursday with few hours to spare due to debt ceiling issue. But the Biden administration is struggling to overcome the hurdles of two senators. It has been a nightmare for the Democrats. According to MSNBC, 68% of the people support infrastructure, 66% support Climate change and 62% support social safety net initiatives. The climate change or global warmings are causing havoc to human lives, hurricane damage, real estate losses, energy costs, pollution, ecological disaster and many more. Not to mention, diseases, medical cost, toxic effect and so on.. All these are estimated to cost U.S almost $1.9 trillion annually or 1.8 percent of U.S. GDP. If we do the math, in 10 years it can cost almost $23 trillion to the U.S economy. So, is it not worth putting just a trillion for next 5 or 10 years?? Very few people realize the catastrophic impact of climate changes. All the politicians need to understand its significance and take appropriate measures sooner than later. But the question is where the money will come from? This brings me to analyze a few things about the taxation policy because this is how the government is planning to fund.
At present, the U.S corporates pay one of the lowest taxes as part of the GDP. Probably, it’s the lowest in U.S history! The tax is just about 1% of GDP. Let me provide some perspectives. Here are some leading countries how they pay corporate taxes as part of their GDP => JAPAN: 4.2%, CANADA: 3.8%, UK: 2.5%, FRANCE: 2.2%, GERMANY: 2.0%, ITALY: 1.9%, USA: 1.0%. Biden Tax cut is not the first proposal that may help the overall economy. Earlier, we saw $1.5 trillion Bush Tax cut in 2009, Trump Tax cut in 2018 and COVID related stimulus totaling about $8.4 trillion (including FED stimulus).
Many people think that increased tax rate would impact the corporate America and the stock market. Yes, that’s true to some extent. But let me analyze what happened when Donald Trump reduced the corporate TAX?? Here are some perspectives for the benefit of the readers. The Trump tax cuts was a failure. Let me tell why? Because it did NOT lead to a significant uptick in economic growth, hiring slowed and wage growth remained lackluster. Corporate tax revenuesfell 31% in the first year after the cut was passed. Overall tax revenues declined as a share of the economy in each of the two years since the tax cut took effect. It helped to boost corporate profits and rich became richer. Many top billionaires did not pay any tax!! Many S&P top companies did NOT pay any tax. Because they were able to play the game of throne.. The Corporate profit ballooned about 115% but they paid less tax. Coincidently, more than 60% of the tax savings went to people in the top 20% of the income ladder, according to the nonpartisan Tax Policy Center. The stock market got thrilled and went up for a couple of quarters but after that everything subsided. And let’s not forget, that year 2018, stock market had negative return. Here is the stock market performance for 2018 after the implementation of tax cut. Dow: -5.6%, S&P: -6.2%, NASDAQ: -3.9%.
Moreover, the COVID relief kick-started the economy and that’s where we are today. It happened, because the money went to people’s hand rather than going to rich people or corporates. The consumer spending went up significantly helping to boost the corporate revenues, profits and ultimately the U.S economy. Hence, if the infrastructure bill gets through then we may see further boom. Agreed, the inflation may go up but that can be controlled by the FED. When an economy grows there will always be some inflation. Moderate inflation is always better than deflation or stagflation.
Historic Minimum Corporate TAX agreed by 136 Countries
On Friday, 10/8, A group of 136 countries have agreed to a global treaty that would tax large multinationals at a minimum rate of 15% and require companies to pay taxes in the countries where they do business. Most of the world's nations have signed up to a historic deal to ensure big companies pay a fairer share of tax. Many of the multinational companies are re-routing their profits through low tax jurisdictions by doing business in the countries where there is no corporate tax or low tax. The Biden administration initiated this and obtained the support from G7 nations in June this year. Now we see 136 countries have joined the force and implementation will start from 2023.
Revenue & Profit growth for 2021, Forecast for 20202
Quarter | Earnings % | Revenue % |
Q1 (reported) | 52.5 | 10.9 |
Q1 (reported) | 89.3 | 19.7 |
Q3 (projected) | 27.6 | 14.5 |
Q4 (projected) | 21.3 | 11.0 |
FY21 (projected) | 41.9 | 14.5 |
FY22 (projected) | 9.4% | 6.5 |
Third quarter earnings will kick-off next week. We will see deceleration in both earnings and revenues. So, we can’t expect significant boost in the stock price. But there are some sectors which can do well. We will see how technology sector will perform. I do not expect earnings explosion from the tech sector. So, will the tech sector continue to lead? So far this year, tech sector is in 5th place as far as ROI is concerned. Thus, we can continue to see some money rotation from tech sector to other sectors. So, should we sit on the sidelines? I personally do not like to be on the sideline and sit with cash. Always, there is something to buy/sell in the stock market. So, I do my due diligence and sell some equities which I feel do not have much potential and accumulate others that I think have better potential in short or long term. But my emphasis is mostly long term. I believe more on investing rather than trading. I do not want to time the market or sit with tons of cash. But it’s always better to have some cash to take advantage of any market pullback or correction.
Sectorial Stock Market Performances
Energy have been top performer in last one year with humongous 87.68% return. Please click below link to view sectorial performances.
Source: Fidelity.com
Now let me discuss this month’s inclusion to my Blog Portfolio.
Cassava Sciences, Inc. (SAVA)
This month I am writing about a stock which may have significant risk and reward ratio depending on how it goes. Those who are in my WhatsApp group may be aware that I have sent many messages about Cassava Sciences (SAVA). Today let me discuss about SAVA and the reason of my interest in this stock.
SAVA is a clinical stage biotechnology company, develops drugs for neurodegenerative diseases, located in Austin, Texas. It has two lead therapeutic product candidate. One is Simufilam, a small molecule drug, which is completed Phase 2b clinical trial for the treatment of Alzheimer's disease. It also has an investigational diagnostic product candidate known as SavaDx, a blood-based (Blood Test) diagnostic to detect Alzheimer's disease. Though, both products are important simufilam happens to be its biggest opportunity. Before I discuss about SAVA and its effective drug trials, let me spend a minute to talk about Alzheimer’s disease (AD). There are more than 6 million Americans of all ages who have Alzheimer's. An estimated 6.2 million Americans aged 65 and older are living with Alzheimer's dementia as of 2021. More than 72% people above the age of 75 or older have Alzheimer’s. This is the 6th biggest cause of death and so far there is no effective treatments. In 2021, Alzheimer's and other dementias (loss of memory) is expected to cost the U.S. $355 billion on drugs and log-term care. According to the World Health Organization, over 50 million people worldwide have dementia with nearly 10 million new diagnosed cases each year. So far, there is no suitable approved treatment available. Biogen’s drug got approval from FDA, but there were lot of criticism about its efficacy, costs and side effect.
Why do I like SAVA?
The National Institutes of Health (NIH) funded 50 patients’ study for simufilam showed that 68% of the patients improved significantly on an average of 6.8% points from baseline and an additional 20% of study subjects declined less than 5 points. Overall, about 98% patients deprived some benefits. The drug showed improvement in 6 months, got better in 9 months and further better in 12 months study. There has never been any drug showed such improvements till date. Based on the current study simufilam has shown far more superiority comparing to Biogen drug which got FDA approval. Though, Eli Lilly drug got FDA breakthrough therapy designation, but SAVA results has shown much more promises thus far. The FDA has authorized to start phase-3 trials in this quarter with more than 100 patients. The company’s mission is to defeat Alzheimer’s disease. So far, the company has been successful, and the results were very good. In addition, the company has SavaDxwhich is a blood-based diagnostic to detect Alzheimer's disease through a simple blood test, possibly years before the appearance of any overt clinical symptoms. In other words, it has two very strong pipeline of products, though main one being simufilam. Just to give a perspective to my readers, when Biogen AD drug “Aduhelm” was approved in June, the valuation of Biogen and Eli Lilly rocketed $19.3B and $28.6B respectively within a week. It costs $56k per annum and requires at least 3 MRIs in the first year. If we compare the results then SAVA’s results has been superior, expected to cost much, much less and has a market capitalization of just $2.06 Billion.
Digging deeper into SAVA Stock Price
For the investors who bought the shares early this year has been phenomenal despite the huge correction in SAVA stock price. The share price started out near $7 in early January but didn’t stay there for long. As company started reporting promising simufilam results for Alzheimer's disease from its 6, 9 and 12 moths, the stock started skyrocketing to as high as $146. After the 12 months results, it was “sell on the news”. Fast forward, in late August short sellers attacked SAVA with essentially a short report called a citizen’s petition where the thesis was that “FDA must stop phase 3 trials to protect patients!!". Well, patients’ safety is undoubtedly a major concern, but the petitioner(s) never showed evidence of any serious safety events in their filing of over 70 pages. The interesting question is why was the safety issue picked by the short petitioner? Because the FDA only halts trials for safety issues. Anyway, with all these news, it was a golden opportunity for the short sellers and hedge funds to smash SAVA and brought the share price to as low as $38. However, the stock recovered in last 2-3 weeks to $70 and now trading at $51.49. The FDA never stopped SAVA to start its Phase-3 clinical trials and they have already started the process. Soon, we may hear first dosing for the first patient in phase-3 trials.
Catalysts
The FDA is very likely going reject the Citizen petitions filed by the short sellers/lawyers. As I said before, there is no substantive facts rather a manipulation by short-sellers represented by their lawyers. In my view, SAVA did not violate or frame any data because it was done by independent third party.
Phase-3 trials is expected to begin in this quarter, and we may see a PR from the company as soon as first dosing takes place for the first participant, hopefully this month or next month.
SAVA has clarified that they are looking for a partnership deal. The company has sufficient fund to carry out the clinical trials, but they don't have all expertise to take it towards FDA approval. Furthermore, it’s a small company so they need enormous resources for sales and marketing. Hence, if a partnership deal is announced then it could be huge.
SAVA is expected to provide more data soon on the Open Label study which is expected to show further convincing data from rest of the open label participants.
There are strong reasons and expectations that FDA could issue a fast track designation to simufilam visualizing the clinical benefits it has shown and unmet need of the drug.
SAVA insiders are holding big positions and have not sold any stock
Ortex estimates that 34.3% of the company's float is currently held in short positions. Any major good news could send this stock rocking.
My View
Meanwhile, the stock bounced back from the low of $38 a few weeks back to $51.49 at the time of writing this blog. Even with this price, those who bought the stock in JAN 2021 would be sitting on X gain. Now the stock is trading at $51.49 which is 65% discount to its 52-weeks high. I bought this stock around $7 took some profit on the way up, then again started accumulating and trimming in between. I still keep accumulating the stock in a small quantity whenever it takes a hit. I am not too much concerned with the day-to-day volatility and my accumulation continues. I believe in the long term prospects of this company based on current results. If simufilam and SavaDx continues to show promises then there is no denying that FDA would approve. I do understand that it still has a long way to go. But visualizing the lack of effective drugs in the market and Biden Administration’s emphasis on Alzheimer’s disease this should get node from FDA. As I said, there is no effective drug for AD in the World today, and the market is humongous. If approved, it can have BLOCKBUSTER potential in multiple of 10s of billions of dollars in revenue. Hence, the stock could rocket but it’s difficult to predict how high it can go!! Some journals came out with absurd price expectation of $3700+ per share. Well, I do not have such ridiculous expectations, but I won’t be surprised if it goes up 5X or 10X. The short seller’s strategy is to frame something to scare the retail investors to run away, so that they can buy at dirt cheap price. Whenever one lawsuits is filled, we see a flood of those one after another like the ants on a queue!! They are backed by many parties/institutions with vested interest. We keep seeing such things in many stocks and more than 80-90% of the cases are invalid allegations. Unfortunately, not many of such folks gets punished and hence they get the liberty to do anything they wish! Sometimes, I see it as positive news because this brings a great opportunity to accumulate a stock which could not have been possible otherwise..
Risks
With all the promises, if the company fails in future clinical trial or FDA does not approve it for some reason, then it could be catastrophic for its share price. However, if it does well then I have already mentioned what to expect. This is a highly volatile stock. The citizen petition is still there and may take time to get out of woods. Partnership is highly likely, but we never know until it happens. So, it could be difficult for the company to afford, or they may have to issue additional shares that may dilute the equities. Of course, that’s nothing new for the biotech companies. Furthermore, no stock is immune to stock market volatility. Hence, SAVA is no exception. But stocks like SAVA are more dependent on its drug trial rather than stock market volatility. It’s extremely risky stock but highly rewarding on how things go. Having said all that, risk averse investors who can’t take volatility and have no patience must avoid this stock. Irrespective of how much research we do future is unpredictable, hence caution is warranted.
My final thoughts
As aforesaid, this stock could be very risky and rewarding too, depending on how it goes further. Thus far, the clinical trials have shown promising results. SAVA has the potential to make a breakthrough which nobody has succeeded till date. If that happens, the investment could bring a phenomenal return on investment. Failure could be catastrophic!! As my readers know, my investment framework is to invest in a phased manner and keep accumulating the shares when it’s cheap and keep trimming when it goes up. It’s a risky investment but I also see abundant opportunity that I can’t ignore. I have invested about 2-3% of my portfolio. I am a growth investor and willing to take a calculated risk. I don’t bother too much about short-term fluctuation and keep a long term vision. As long as I think that a stock has potential, I keep accumulating but once I feel that it’s not worth taking risk or as situation demands, I get out irrespective of price. Each investor must do their due diligence before putting their hard-earned money and determine what’s best for them. This is my strategy but I may be wrong!!
Shesa’s Blog Portfolio (As of OCT 10, 2021)
Equity | Suggested Price | Current Price | Suggested Date | % Change | My View |
STOCK (All prices are in USD) | |||||
12.9 | 142.9 | 1/25/13 | 1008% | HOLD | |
47 | 330.05 | 11/13/13 | 602% | HOLD (Trimmed) | |
77.18 | 354.96 | 12/12/13 | 360% | HOLD | |
311.73 | 3288.62 | 4/12/14 | 955% | HOLD | |
36.53 | 35.61 | 5/28/18 | -3% | HOLD (Trimmed) | |
134.81 | 1378.03 | 11/25/18 | 922% | HOLD | |
297.57 | 632.66 | 1/6/19 | 113% | HOLD | |
20.16 | 13.22 | 12/10/19 | -34% | HOLD (Trimmed) | |
87.53 | 104.33 | 9/1/19 | 19% | HOLD | |
4.27 | 35.83 | 1/29/20 | 739% | HOLD | |
12 | 23.83 | 3/22/20 | 99% | HOLD (Trimmed) | |
76.91 | 100.58 | 4/19/20 | 31% | HOLD (Trimmed) | |
54.59 | 132.08 | 5/25/20 | 142% | HOLD (Trimmed) | |
45.3 | 154.36 | 6/28/20 | 241% | BUY - long term | |
19.58 | 31.55 | 8/2/20 | 61% | HOLD/Accumulate | |
51.61 | 70.12 | 10/18/20 | 36% | HOLD (Trimmed) | |
62.71 | 47.26 | 11/21/20 | -25% | HOLD (Trimmed) | |
14.39 | 6.49 | 2/14/21 | -55% | Accumulate | |
27.98 | 27.19 | 4/25/21 | -3% | Accumulate | |
44.41 | 23.45 | 5/31/21 | -47% | HOLD | |
5.39 | 5.72 | 7/18/21 | 6% | Accumulate | |
8.11 | 8.67 | 8/27/21 | 7% | Accumulate | |
51.49 | 51.49 | 10/10/21 | 0% | NEW ADDITION | |
ETF | |||||
139.1 | 257.18 | 8/16/15 | 85% | HOLD | |
70.23 | 62.79 | 1/3/21 | -11% | HOLD/Accumulate | |
MUTUAL FUND | |||||
11.46 | 21.61 | 3/1/13 | 89% | HOLD | |
59.45 | 203.73 | 12/20/14 | 243% | HOLD | |
9.05 | 24.02 | 1/15/16 | 165% | HOLD | |
37.32 | 97.04 | 3/20/16 | 160% | HOLD | |
43.66 | 86.52 | 9/24/17 | 98% | HOLD | |
Positions CLOSED since last Blog
Bed Bath & Beyond (BBBY): SOLD on 10/4 @17.85. Profit +48%.
That’s all for today. Wish you great investing! Stay tuned for my next blog. Thanks for your time.
Disclaimer: This blog is meant to provide my opinion only. The information provided is to the best of my knowledge but may not be accurate. I do NOT provide any professional recommendation to buy/sell any stock, ETF, mutual fund, or any other security(s). As an investor, it’s your hard-earned money and you decide what is best for you. The above are merely my own opinions on what I do. Please contact a professional money manager to buy/sell any security. I do not charge any fees or commission by writing the blog except anything from Google AdSense. I have position(s) on whatever security I put on my blog portfolio and avoid including any security that I do not own or follow. Anybody buying or selling the equities mentioned here is their own risk.
Note: Click on Blog archives to read all my Blogs and updates.
Comments
Post a Comment